Zerodha (Trading Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Review By Dilip Davda on June 26, 2021
• WNL is engaged in the manufacturing of Nutraceutical/Ayurvedic/Food Supplement products.
• Its top line for all these years is almost stagnant with a marginal rise in the bottom line.
• Based on financial parameters issue is priced exorbitantly.
• The company operates in a highly competitive field and hence will see pressure on margins.
• There is no harm in giving this IPO a 'MISS'.
ABOUT COMPANY:
Walpar Nutritions Ltd. (WNL) is engaged in the manufacturing of a wide range of Nutraceutical, Ayurvedic, Cosmeceuticals, Sexual Wellness and Food Supplement products. The company develops, manufactures and commercializes Herbo-Nutraceutical products including marketing, sales, quality assurance, distribution, compliance and regulatory aspects under Nutraceuticals. It has product approvals from FSSAI and Ayush. It has applied for patents for its three products.
WNL has developed more than 100 formulations and 1000 brands for the third party for the domestic market. Currently, it has an installed capacity of manufacturing 30 lakhs tablets, 12.5 lakhs capsules, 1.5 lakhs oral liquids and 2.00 lakhs sachets per month. The company is also engaged in the trading of raw material used in the manufacturing of nutraceutical products. As of December 31, 2020, WNL has a total strength of 25 employees (excluding contract labourers in various departments. The company exclusively rely on a third party for logistics on procurement and supply of goods. It operates in a highly competitive field.
ISSUE DETAILS/CAPITAL HISTORY:
To part finance its plans for investment in subsidiary (Rs. 1.80 cr.), working capital (Rs. 2.90 cr.), general corpus fund (Rs. 1.50 cr.) needs, WNL is coming out with a maiden public issue of 1200000 equity share of Rs. 10 each at a fixed price of Rs. 55 per share to mobilize Rs. 6.60 cr. The issue opens for subscription on June 30, 2021, and will close on July 05, 2021. Minimum application is to be made for 2000 shares and in multiples thereon, thereafter. Post allotment, shares will be listed on NSE SME Emerge. The issue constitutes 26.42% of the post issue paid-up capital of the company. WNL will be spending Rs. 0.40 cr. for this IPO process.
The issue is solely lead managed by Beeline Broking Ltd., Skyline Financial Services Pvt. Ltd. is the registrar and Nikunj Stock Brokers Ltd. is the market maker for this issue.
Having issued initial equity at par, the company raised further equity at Rs. 50 per share in January 2021. The average cost of acquisition of shares by the promoters is Rs. 10 per share.
Post issue company's current paid-up equity capital of Rs. 3.34 cr. will stand enhanced to Rs. 4.54 cr. At the issue price, WNL is looking for a market cap of Rs. 24.98 cr.
FINANCIAL PERFORMANCE:
On the financial performance front, for the last three fiscals, WNL (as a partnership organization) has reported turnover/net profit of Rs. 6.45 cr. / Rs. 0.003 cr. (FY18), Rs. 12.83 cr. / Rs. 0.07 cr. (FY19) and Rs. 16.71 cr. / Rs. 0.12 cr. (FY20). For the period April 01, 2020, to December 03, 2020, it posted a turnover of Rs. 11.36 cr. with a net profit of Rs. 0.06 cr. Post conversion into a public limited company, it has reported a turnover of Rs. 1.43 cr. with a net profit of Rs. 0.23 cr. for the period December 04, 2020, to December 31, 2020. If we combine FY21 9M financial data, then it has earned a net profit of Rs. 0.29 cr. on a turnover of Rs. 12.79 cr. for the period. Super earnings post-conversion for less than a one-month period is the most surprising one and raises concern.
For the last three fiscals, WNL has posted an average EPS of Rs. 0.28 and an average RoNW of 5.45%. The issue is priced at a P/BV of 5.29 based on its NAV of Rs. 10.39 as of December 31, 2020, and at a P/BV of 2.24 based on its post-issue NAV of Rs. 24.52 per share.
If we annualize FY21 earnings (that includes super earnings for just 28 days) and attribute it on fully diluted post issue equity then the asking price is at a P/E of 64 and based on FY20 earnings, it is priced at a P/E of 211 plus, making this IPO exorbitantly priced.
COMPARISON WITH LISTED PEERS:
As per offer documents, WNL has shown Earum Pharma and Valencia Nutrition as its listed peers. They are currently trading at a P/E of 00 and 00 (as of June 25, 2021). However, they are not fully comparable on an apple to apple basis.
DIVIDEND POLICY:
WNL has not paid any dividend since incorporation. Post listing it will follow a prudent dividend policy based on its financial performance and future prospects.
MERCHANT BANKER'S TRACK RECORDS:
This is the 8th mandate from this LM's stable in the last five fiscals including the ongoing one. Out of the last 7 listings, 1 opened at discount, 1 at par and the rest in premiums ranging from 0.137% to 10% on a listing day.
Review By Dilip Davda on June 26, 2021
DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. My reviews do not cover GMP market and operators game plans. Readers must consult a qualified financial advisor before making any actual investment decisions, based the on information published here. With entry barriers, SEBI wants only well-informed investors to participate in such offers. With crazy listings in the recent past, SME IPOs drew the attention of investors across the board and lead to seer madness. However, as SME issues have entry barriers and continued low preference from the broking community, any reader taking decisions based on any information published here does so entirely at their own risk. The above information is based on information available as of date coupled with market perceptions. The Author has no plans to invest in this offer.
About Dilip Davda
Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.
Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.
(Dilip Davda -SEBI registered Research Analyst-Mumbai,
Registration no. INH000003127 (Perpetual)
Email id: dilip_davda@rediffmail.com ).
The initial public offer (IPO) of Walpar Nutritions Limited offers an early investment opportunity in Walpar Nutritions Limited. A stock market investor can buy Walpar Nutritions IPO shares by applying in IPO before Walpar Nutritions Limited shares get listed at the stock exchanges. An investor could invest in Walpar Nutritions IPO for short term listing gain or a long term.
Read the Walpar Nutritions IPO recommendations by the leading analyst and leading stock brokers.
Walpar Nutritions IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the Walpar Nutritions IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts in the above answer.
Our recommendation for Walpar Nutritions IPO is to avoid.
As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to avoid the Walpar Nutritions IPO.
The Walpar Nutritions IPO allotment status will be available on or around July 8, 2021. The allotted shares will be credited in demat account by July 9, 2021. Visit Walpar Nutritions IPO allotment status to check.
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
RHP
